相关实验视频

Updated: Mar 8, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

DDR2通过激活AMPK/ACC通路来改善非酒精性肝肥胖症

Manyu Guo¹, Li Lin¹, Yiming Wang¹

¹Department of Biochemistry and Molecular Biology, Metabolic Disease Research Center, School of Basic Medicine, Anhui Medical University, Hefei, 230032, China.

Scientific reports

|March 6, 2026

概括

与代谢功能障碍相关的脂肪性肝病 (MASLD) 涉及减少DDR2表达. 恢复DDR2水平通过激活AMPK/ACC通路来抑制肝脂肪的积累,为MASLD提供了潜在的治疗标.

科学领域:

肝病学肝病学是一种肝病学.
分子生物学分子生物学
生物化学生物化学

背景情况:

与代谢功能障碍相关的脂肪性肝病 (MASLD),以前称为NAFLD,是一个全球性的健康问题,缺乏有效的治疗方法.
了解MASLD的分子驱动因素对于开发干预措施至关重要.
DDR2是一种受体氨酸激酶,涉及纤维化和细胞粘附,但其在MASLD中的作用尚不清楚.

研究的目的:

研究DDR2在MASLD发展和进展中的作用和机制.
确定DDR2是否可以在MASLD中调制以获得治疗效益.

主要方法:

从饮食诱导和遗传肥胖的小鼠模型中评估了肝脏组织中的DDR2表达.
利用RT-qPCR,西式斑点和油红色O染色来评估DDR2对肝细胞脂质合成的影响.
检查了在db/db和高脂肪饮食 (HFD) 中的MASLD进展,养具有不同DRR2水平的小鼠.

主要成果:

肝脏DDR2表达在HFD养和db/db养小鼠中显著下降.
过度表达DDR2减少了肝脏甘油三积累和脂质合成基因表达.
降低DDR2加剧的脂质积累和相关的基因表达.
DDR2激活增强了AMPK/ACC酸化,抑制了肝细胞脂生成.

结论:

在MASLD模型中,DDR2表达减少.
DDR2通过AMPK/ACC通路抑制肝细胞脂质发生.
对于管理MASLD来说,DDR2代表了一个潜在的治疗目标.

关键词:

在 ACC ACC ACC ACC ACC ACC ACC ACC ACC ACC ACC 这就是AMPKK.这就是DDR2 DDR2.马斯尔德马斯尔德是什么意思

更多相关视频

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model

Published on: December 2, 2022

相关概念视频

cAMP-dependent Protein Kinase Pathways

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...